Literature DB >> 16998506

The CHEK2 gene and inherited breast cancer susceptibility.

H Nevanlinna1, J Bartek.   

Abstract

Checkpoint kinase 2 (CHEK2, Chk2) emerges as an important signal transducer of cellular responses to DNA damage and a candidate tumor suppressor whose defects contribute to molecular pathogenesis of diverse types of human malignancies, both sporadic and hereditary. Here, we briefly outline the molecular properties, regulation and physiological role of CHEK2, and review in more detail its defects that predispose to tumors, with particular emphasis on familial breast cancer. The frequency, penetrance and epidemiological as well as clinical significance of the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T, are highlighted in more depth, and additional CHEK2 mutations and their cancer relevance are discussed as well. These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression. Finally, the potential value of information about the CHEK2 status in family counseling and optimizition of individualized cancer treatment is discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998506     DOI: 10.1038/sj.onc.1209877

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  76 in total

1.  Cross-talk between Chk1 and Chk2 in double-mutant thymocytes.

Authors:  Kathrin Zaugg; Yu-Wen Su; Patrick T Reilly; Yasmin Moolani; Carol C Cheung; Razquallah Hakem; Atsushi Hirao; Qinghua Liu; Stephen J Elledge; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-26       Impact factor: 11.205

2.  Identification of Novel Susceptibility Genes for Breast Cancer - Genome-Wide Association Studies or Evaluation of Candidate Genes?

Authors:  Alfons Meindl
Journal:  Breast Care (Basel)       Date:  2009-04-24       Impact factor: 2.860

Review 3.  Inherited pancreatic cancer.

Authors:  Fei Chen; Nicholas J Roberts; Alison P Klein
Journal:  Chin Clin Oncol       Date:  2017-12

Review 4.  Breast cancer in an 18-year-old female: A fatal case report and literature review.

Authors:  Maciej Jóźwik; Renata Posmyk; Marcin Jóźwik; Andrzej Semczuk; Magdalena Gogiel-Shields; Marta Kuś-Słowińska; Magdalena Garbowicz; Mark Klukowski; Jacek Wojciechowicz
Journal:  Cancer Biol Ther       Date:  2018-07-03       Impact factor: 4.742

5.  Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.

Authors:  Amir Sonnenblick; Aviad Zick; Myriam Maoz; Sherri Cohen; Luna Kadouri; Tamar Peretz; Ayala Hubert
Journal:  Mol Clin Oncol       Date:  2018-03-09

6.  Estrogen induces RAD51C expression and localization to sites of DNA damage.

Authors:  Anya Alayev; Rachel S Salamon; Subrata Manna; Naomi S Schwartz; Adi Y Berman; Marina K Holz
Journal:  Cell Cycle       Date:  2016-10-18       Impact factor: 4.534

7.  Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.

Authors:  Bella Kaufman; Yael Laitman; Jacek Gronwald; Robert Winqvist; Arvids Irmejs; Jan Lubinski; Katri Pylkäs; Janis Gardovskis; Edvins Miklasevics; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-07-17       Impact factor: 2.375

Review 8.  The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer.

Authors:  Huy Q Ta; Daniel Gioeli
Journal:  Endocr Relat Cancer       Date:  2014-08-05       Impact factor: 5.678

9.  Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.

Authors:  Huy Q Ta; Melissa L Ivey; Henry F Frierson; Mark R Conaway; Jaroslaw Dziegielewski; James M Larner; Daniel Gioeli
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

10.  CHEK2 1100 delC mutation in Russian ovarian cancer patients.

Authors:  Nadezhda Yu Krylova; Daria N Ponomariova; Natalia Yu Sherina; Natalia Yu Ogorodnikova; Denis A Logvinov; Natalia V Porhanova; Oksana S Lobeiko; Adel F Urmancheyeva; Sergey Ya Maximov; Alexandr V Togo; Evgeny N Suspitsin; Evgeny N Imyanitov
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.